Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Distress Tolerance - Benzodiazepine Discontinuation
- Development stage
- Unknown
- Lead developer
- Boston Medical Center
- Modality
- Small Molecules
01
Overview
Distress Tolerance - Benzodiazepine Discontinuation (DT-BD) is a multi-modal therapeutic intervention developed by Boston Medical Center specifically for patients receiving opioid agonist therapy (OAT) who are seeking to discontinue benzodiazepine use. The intervention combines a psychosocial behavioral program with a structured pharmacological taper. The behavioral component integrates elements of Acceptance and Commitment Therapy (ACT), Relapse Prevention (RP), and interoceptive exposure techniques to enhance a patient's ability to tolerate the physical and emotional distress associated with withdrawal. The pharmacological component involves a medically supervised 9-week gradual reduction of the patient's benzodiazepine dosage, with specific anchor points for dose reduction to ensure a systematic discontinuation process.
- Other names
- benzodiazepine-Boston Medical CenterBZD discontinuation protocolDistress Tolerance and Benzodiazepine Discontinuation in Opioid Agonist Therapy
02
Targets
GABAA (Gamma-aminobutyric acid receptor)
Beyond the preview
Go deeper on Distress Tolerance - Benzodiazepine Discontinuation.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Distress Tolerance - Benzodiazepine Discontinuation.